deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02913326

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period

Sponsor: Boehringer Ingelheim

Conditions Thromboembolism
Interventions Dabigatran etexilate Warfarin
Updated 17 times since 2017 Last updated: Aug 9, 2019 Started: Dec 13, 2016 Primary completion: Jun 22, 2018 Completion: Jun 22, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02913326, this PHASE3 trial focuses on Thromboembolism and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 17 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2019 · 13 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Sep 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Aug 2018 — Sep 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  4. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Oct 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  7. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  8. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  9. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  10. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  12. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amadora, Portugal , Amsterdam, Netherlands , Bangalore, India , Barnaul, Russia , Berlin, Germany , Bordeaux, France , Cremona, Italy , Essen, Germany , Gdansk, Poland , Hamburg, Germany and 22 more locations